 SPARTA, N.J., Nov. 12, 2020 GLOBE NEWSWIRE -- PLx Pharma Inc. NASDAQ: PLXP PLx or the Company, a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuardTM delivery system to provide more effective and safer products, VAZALORETM 325 mg and VAZALORETM 81 mg referred to together as VAZALORETM, announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020. 